Quantcast

Latest Bare-metal stent Stories

2010-05-12 06:30:00

NATICK, Mass., May 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark approval for its TAXUS® Element(TM) Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent (DES) technology. This approval includes a specific indication for the treatment of diabetic patients. The TAXUS Element Stent System incorporates a platinum chromium alloy with an innovative stent design and an...

2010-05-05 15:17:00

Study highlights: Non-cardiac surgery performed in patients who had coronary stents implanted within the previous six weeks is associated with an increased risk of heart complications and death. Patients who required stent implantation following a recent heart attack were at greater risk than those who had stents implanted due to chronic disease. The level of risk was similar for patients treated with bare metal stents and drug-eluting stents. DALLAS, May 5 /PRNewswire-USNewswire/ --...

2010-05-05 08:50:00

WALTHAM, Mass., May 5 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, when Abbott Vascular's Xience V and Boston Scientific's Promus entered the Japanese drug-eluting stent market in Q1 2010, both companies picked up share from competitors Medtronic and Cordis. In its peak sales month, Xience V was used in over 50% of drug-eluting stent procedures, and averaged a unit share of just less than 40% for the first...

2010-05-05 11:52:40

Patients who can postpone non-cardiac surgery for at least six weeks after receiving a coronary stent are less likely to suffer reduced blood flow to the heart, heart attack and death than those who have surgery sooner, Scottish researchers report in Circulation: Cardiovascular Interventions, an American Heart Association journal. Coronary stents are small tubes of wire-metal mesh that doctors insert into constricted arteries to increase blood flow by permanently holding the arteries open. A...

2010-03-15 15:42:00

NATICK, Mass. and ATLANTA, March 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2(TM)( )Paclitaxel-Eluting Stent System or the Express® bare-metal stent. The results demonstrated that the TAXUS®...

2010-03-15 10:16:00

NATICK, Mass. and ATLANTA, March 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS® Element(TM) Paclitaxel-Eluting Stent System compared to the TAXUS® Express2(TM) Paclitaxel-Eluting Stent System. The results also reported a similar safety profile and...

2010-03-10 07:30:00

NATICK, Mass., March 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements at the 59th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 13-16 in Atlanta. "We look forward to announcing 12-month results from the PERSEUS clinical program, which will provide important data on our third-generation drug-eluting stent, the TAXUS® Element(TM)...

2010-02-11 22:26:00

DALLAS, Feb. 11 /PRNewswire-USNewswire/ -- Volunteers and staff of the American Heart Association extend their thoughts and well wishes to former President Bill Clinton upon the reports that he has undergone a procedure to insert stents to widen narrowed coronary arteries. President Clinton, who underwent quadruple coronary bypass surgery in 2004, partnered with the Association through his Foundation to jointly form the Alliance for a Healthier Generation to reduce the prevalence of...

2010-01-28 01:00:00

LONDON, Jan. 28 /PRNewswire/ -- Based on its recent research on the medical devices market, Frost & Sullivan presents Japan Stent Technology with the 2009 European Frost & Sullivan Award for Enabling Technology for its contributions to advancing localized drug delivery in the coronary care segment. The company is on the cutting edge of a new era in medical device care that is witnessing a merging of device and pharmaceutical therapy. Drug-hybrid technologies provide a revolutionary...

2009-12-08 13:34:00

NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) http://www.reportlinker.com/p0166835/European-Markets-for-Drug-Eluting-and-Bare-Metal-Stents-2009-15-Countries.html The European market, as defined in this report, encompasses Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands, and Luxemburg),...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related